Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin

Hepato-Gastroenterology

Volumn 56, Issue 89, 2009, Pages 218-222

  Varghese, Rosh ^a   Al Khaldi, J ^b   Asker, H ^b   Fadili, A A ^a   Al Ali, J ^a   Hassan, F A ^a  

^a MUBARAK AL KABEER HOSPITAL   (Kuwait)

^b AL AMIRI HOSPITAL   (Kuwait)

Author keywords

Chronic Hepatitis C; Genotype 4; Peginterferon alpha2 Sustained virological response

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTIVIRAL AGENTS; BIOPSY; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 64949119373     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. WHO. Hepatitis C- global prevalence(update). Wkly Epidemiol Rec 1997;7 2:341-348.
2. Seeff LB: Natural history of chronic hepatitis C. Hepatology 2002; 36(suppl):pS35-46.
3. Straser DB, Seeff LB: The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1996; 8:324-328.
4. National institute of Health consensus Development Conference statement: management of hepatitis C. Hepatology 2002; (suppl 1)p:S3-20.
5. Strader DB, Wright T, Thomas DL and Seef LB: Diagnosis, Management and Treatment of Hepatitis C. Hepatology 2004; 39:1147-1171.
6. Manna MP, McHutchison JG, Gordon SC, Rustigi V K, Shiffman M, Reindollar R, Goodman Z D, et al: Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: randomized trial. Lancet 2001; 358:958-965.
7. Fried MW, Shiffman M L, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Hauscinger D, et al: Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
8. Hadziyannis SJ, Setle H, Morgan TR, Balan V, Diago M, Marcel]in P, Ramadori G, et al: Peginterferon alpha-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Inter Med 2004; 140:346-355.
9. Nguyen MH, Keeffe EB:Chronic Hepatitis C: Genotypes 4 to 9. Clin Liver Dis 2005; 9: 411-426.
10. Ray SC, Arthur RR, Carella A, et al: Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000; 182:698-707.
11. Shobokshi OA, Serebour FE, Skakni L, et al: Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999; 58:44-48.
12. Hasan F, Asker H, Al-Khaldi J, et al: Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99:1733-1737.
13. Hasan F, Asker H, Al-Khaldi J, et al: Pegylated interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C genotype 4. AASLD 2003; 38:629A.
14. Angelico M, Renganathan E, Gandin C, et al: Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. J Hepatol 1997; 26:236-243.
15. Siebert U, Sroczynski G I, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, Hutchison JG, Wong JB: Cost-Effectiveness of Peginterferon alpha-2b Plus Ribavirin compared with interferon alpha-2b plus Ribavirin for initial treatment of chronic hepatitis C. J Hepatol 2002; 36 (suppl1):129-130.
16. Thakeb F, Omar M, Bilharz T, et al: Randomized controlled trial of peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus-genotype 4 among Egyptian patients. Hepatology 2003; 38:278A.
17. Boyer JL, Chang EB, Collyar DE, DeLeve LD, Feinberg J, Judge TA, et al: National Institutes of Health consensus development conference statement: management of hepatitis C. June 10-12 2002. Hepatology 2002; 36(Suppl 1):S3-20.
18. Gish RG: Treating hepatitis C: the state of the art. Gastroenterol Clin N Am 2004; 33: S1-S9
19. Al-faleh FZ, Hadad Q, Khuroo MS, et al: Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004; 24:568-574.
20. Al-Traif I, Handoo FA, Al-Jumah A, Al-Nasser M: Chronic hepatitis C - Genotypes and response to anti-viral therapy among Saudi patients. Saudi Med J 2004; 25:1935-1938.
21. Shobokshi OA, Serebour FE, Skakni L, et al: Efficacy of pegylated (40 KDA) IFN alfa-2a (PEGASYS) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia. J Hepatol 2002; 36(Suppl 1):129.
22. El-Zayadi AR, Attia.M, Barakat E.M.F, Badran H.M, Hamdy.H et al: Response of Hepatitis C Genotype-4 Naive patients to 24 weeks of Peg-Interferon-alpha2b/Ribavirin or Induction-Dose Interferon-alpha2b/ Ribavirin/Amantidine: A non-randomised controlled study. Am J Gastroenterolgy 2005; 100:2447-2452.
23. Al-Faleh FZ, Aljumah A, Rezeig M, et al: Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study. J Viral Hepat 2000; 7:287-291
24. Heathacote EJ, Mitchell L, Shiffman W: Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-1680.
25. Marcellin P, Roberts S, Alberti A, et al: Sustained viro]ogical and biochemical response to peginterferon alpha-2a plus ribavirin in patients with chronic hepatitis C and compensated cirrhosis/bridging fibrosis. Hepatology 2004; 40: 531A.
26. Charlton MR, Pockros PJ, Harrison SA: Impact of Obesity on treatment of Chronic Hepatitis C. Hepatology 2006; 43:1177-1186.
27. McCullough AJ: Obesity and its nurturing effect on hepatitis C. Hepatology 2003; 38: 557-559.
28. Lamb MW, Martin NE: Weight-based versus fixed dosing of peginterferon(40kDa) alfa-2a. Ann Pharmacotherapy 2002; 36:933-935.
29. Glue P, Fang JWS, Rouzier-Panis R, et al: Pegylated interferon-alpha 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Chin Pharmacol Ther 2000; 68:556-567.